GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 45 filers reported holding GRITSTONE ONCOLOGY INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $46,260 | +26.0% | 18,000 | 0.0% | 0.00% | – |
Q4 2023 | $36,720 | +18.6% | 18,000 | 0.0% | 0.00% | – |
Q3 2023 | $30,960 | -11.8% | 18,000 | 0.0% | 0.00% | – |
Q2 2023 | $35,100 | -79.8% | 18,000 | -57.3% | 0.00% | – |
Q1 2022 | $174,000 | -67.8% | 42,200 | +0.2% | 0.00% | – |
Q4 2021 | $541,000 | +52.0% | 42,100 | +27.6% | 0.00% | – |
Q3 2021 | $356,000 | +18.3% | 33,000 | 0.0% | 0.00% | – |
Q2 2021 | $301,000 | +30.9% | 33,000 | +35.2% | 0.00% | – |
Q1 2021 | $230,000 | +42.9% | 24,400 | -40.2% | 0.00% | – |
Q4 2020 | $161,000 | +49.1% | 40,800 | 0.0% | 0.00% | – |
Q3 2020 | $108,000 | -63.6% | 40,800 | -8.9% | 0.00% | – |
Q2 2020 | $297,000 | +92.9% | 44,800 | +69.7% | 0.00% | – |
Q1 2020 | $154,000 | -7.8% | 26,400 | +41.9% | 0.00% | – |
Q4 2019 | $167,000 | +3.7% | 18,600 | 0.0% | 0.00% | – |
Q3 2019 | $161,000 | +10.3% | 18,600 | +42.0% | 0.00% | – |
Q2 2019 | $146,000 | -48.8% | 13,100 | -34.5% | 0.00% | – |
Q3 2018 | $285,000 | – | 20,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 3,561,150 | $9,152,156 | 8.87% |
Affinity Asset Advisors, LLC | 2,390,600 | $6,143,842 | 0.76% |
Redmile Group, LLC | 5,755,075 | $14,790,543 | 0.54% |
IRONWOOD INVESTMENT MANAGEMENT LLC | 157,603 | $405,040 | 0.20% |
Frazier Life Sciences Management, L.P. | 1,030,878 | $2,649,356 | 0.11% |
Artal Group S.A. | 1,030,952 | $2,649,547 | 0.07% |
TWIN PEAKS WEALTH ADVISORS, LLC | 40,314 | $103,607 | 0.06% |
Artia Global Partners LP | 95,170 | $244,587 | 0.05% |
SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 247,607 | $636,350 | 0.03% |
CORNERCAP INVESTMENT COUNSEL INC | 76,811 | $197,404 | 0.03% |